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ABSTRACT 
Objective 
National clinical guidelines for childhood wheeze exist, yet despite being one of the commonest 
reasons for childhood Emergency Department (ED) attendance, significant variation in practice 
occurs in other settings.  We therefore evaluated practice variations of ED clinicians in the UK and 
Ireland. 
Design 
Two-stage survey undertaken in March 2013.  Stage one examined department practice, and stage 
two assessed ED consultant practice in acute childhood wheeze. Questions interrogated 
pharmacological and other management strategies, including inhaled and intravenous (IV) therapies. 
Setting and participants 
Member departments of Paediatric Emergency Research in the United Kingdom and Ireland (PERUKI) 
and ED consultants treating children with acute wheeze. 
Results 
30 EDs and 183 (81%) clinicians responded.  29 (97%) EDs had wheeze guidelines and 12 (40%) had 
care pathways. Variation existed between clinicians in dose, timing and frequency of inhaled 
bronchodilators across severities. When escalating to IV bronchodilators 99 (54%) preferred 
salbutamol first line, 52 (28%) magnesium sulphate (MgSO4) and 27 (15%) aminophylline.  87 (48%) 
administered IV bronchodilators sequentially and 30 (16%) concurrently, with others basing 
approach on case severity. 146 (80%) continued inhaled therapy after commencing IV 
bronchodilators.  Of 170 who used IV salbutamol, 146 (86%) gave rapid boluses, 21 (12%) a longer 
loading dose, and 164 (97%) an ongoing infusion, each with a range of doses and durations.  Of 173 
who used IV MgSO4, all used a bolus only.  41 (24%) used non-invasive ventilation. 
 
  
Conclusions 
Significant variation in ED consultant management of childhood wheeze exists despite the presence 
of national guidance. This reflects the lack of evidence in key areas of childhood wheeze and 
emphasises the need for further robust multi-centre research studies. 
  
INTRODUCTION 
Asthma is the commonest chronic medical condition of childhood, with rates in the UK and Ireland 
amongst the highest in the world.1-4  It remains a significant cause of mortality and morbidity and the 
NHS spends £1 billion on asthma annually, with costs higher in children than adults.4  In the context 
of increasing childhood admission rates asthma accounts for 64-73% of those for chronic conditions, 
and wheezing is one of the commonest reasons for hospitalisation overall.5,6  Whilst there is 
variation in severity and pathophysiology with overlap between asthma and viral induced wheeze 
(VIW), wheezing is consistently identified as a leading presentation to Emergency Departments (EDs) 
in other healthcare settings.7-8 
National guidelines and quality standards exist for the management of wheezing. 9-11 Many 
recommendations derive from high quality studies, but some are based on lesser evidence or expert 
consensus.  Paucity of evidence results in guidance which cannot provide detail in some areas, 
potentially leading to individual interpretation and practice variation as in other systems. 12,13   This 
may contribute to differences in admission rates, bed days and length of stay across English primary 
care trusts.5  
Practice variation may result in poorer health outcomes, unnecessary medical treatments, and 
increased strain on the healthcare system.14 Determining baseline practice and identifying variation 
in wheeze management will highlight areas where implementing existing guidance could improve 
care, and identify key areas for future research. 
We aimed to determine whether variation exists in the clinical care of acute severe childhood 
wheeze across the UK and Ireland through a survey completed by senior clinical decision makers.  
The survey examined differences in approach to severe wheeze, and the use of inhaled, oral, and 
intravenous (IV) therapies. 
 
 
  
METHODS 
Paediatric Emergency Research in the United Kingdom and Ireland (PERUKI)15 sites participated in a 
two-stage survey via Bristol Online Surveys.TM  Stage one assessed department practice, including 
information on clinical practice guidelines (CPG), care pathways (CP), and site-specific features 
including admission location.  In stage two consultants provided information on personal practice 
including assessment and management, inhaled and IV bronchodilators, escalation of care, and 
alternative treatments.  Returns were collated using Microsoft Excel 2010 and descriptive analysis 
undertaken.  PERUKI is a research collaborative of individuals and departments from England, 
Ireland, Northern Ireland, Scotland and Wales which comprises paediatric-specific and mixed adult 
and paediatric EDs that represent secondary and tertiary care.15  Further information is available at 
www.peruki.org.     
ETHICS 
This was confirmed as service evaluation by the research design service at the study lead site.  
 
RESULTS 
Thirty centres participated, 183/226 (81%) consultants completed the survey.  Responses were 
obtained from a range of regions, department types and specialties (Table 1).  Twenty-nine (96.7%) 
departments had a CPG, 12 (40%) had a CP.  All CPGs reflected national guidance with variations 
mainly in drug and dose selection. Twenty (66.7%) described specific admission locations for children 
receiving IV therapy.  In 15 (75%) this included a Paediatric High Dependency Unit, in 7 (35%) an 
inpatient ward. In 5 (25%) this included Paediatric Intensive Care (PIC) with 2 mandating PIC if on IV 
salbutamol. 
 
 
 
 
  
Assessment and general approach 
Most clinicians (113, 61.7%) adopt the same approach in all children 1 year and older.  70 (38.3%) 
modify clinical care depending on whether the diagnosis is asthma or VIW, with several stating they 
are less likely to prescribe steroids for VIW.  Minor variations exist in intensity of inhaled 
bronchodilators and timing of IV therapy. Most clinicians use BTS/SIGN criteria9 to assess severity, 
the most common being “inability to complete sentences, too breathless to talk/feed” (180, 98.4%), 
and hypoxia (177, 96.7%).  106 (57.9%) class episodes as severe if “more than one (but not 
necessarily all) are present”.  156 (85.2%) had a peak expiratory flow rate meter (PEFR), but only 22 
(14.1%) always use this to assess severity. Those who “sometimes” use PEFR meters do so in “older 
children”, or those with known PEFR. (Table 2) 
 
Inhaled bronchodilators 
All clinicians use inhaled salbutamol.  117 (63.9%) use nebulisers in the presence of hypoxia, and 
metered dose inhalers (MDI) in its absence, most commonly giving three doses initially followed by 
reassessment.  173 (94.6%) use ipratropium bromide at least sometimes; 75 (43.4%) do so 
immediately, 67 (38.7%) if no response to the first salbutamol dose.  Dosages of both vary in general 
increasing with age, though in some cases the same dose is given across all age ranges, most 
noticeably in salbutamol MDI. (Table 3) 
 
Steroids 
All use prednisolone 1-2 mg/kg as the oral steroid of choice; none use dexamethasone.  181 (98.9%) 
use hydrocortisone as the IV steroid of choice.  73 (39.8%) use IV steroids “only if oral is not 
tolerated”, 46 (25.1%) use IV “when giving IV bronchodilators regardless of whether oral steroid has 
been given”, and 27 (14.8%) use IV “when giving IV bronchodilators if oral steroid has not been 
given”.  None use inhaled steroids acutely. 
 
  
Escalating to intravenous therapy 
170 (92.9%) escalate for deteriorating severe wheeze, 166 (90.7%) for life-threatening wheeze, and 
141 (77%) if there is no response to inhaled bronchodilators.  167 (91.8%) require more than one 
criterion; 172 (93.9%) use these on a case-by-case basis.  Low numbers use set criteria such as time 
since starting or total accrued dose of inhaled therapy. 99 (54.1%) use salbutamol as first line IV 
therapy, 52 (28.4%) magnesium sulphate and 27 (14.8%) aminophylline.  87 (47.5%) give these 
sequentially depending on response, 30 (16.4%) give them concurrently.  146 (79.8%) continue 
inhaled bronchodilators while on IV therapy. 
 
Intravenous bronchodilators 
170 (92.9%) use IV salbutamol, though in a range of strategies and doses.  For the purposes of this 
study a continuous infusion was defined as a “weight based rate (micrograms/kg/min) with no fixed 
endpoint”; a loading dose as a “weight based rate (micrograms/kg/min) given for a set period of 
time”; and a bolus as a “weight based dose (micrograms/kg)”.  Five general strategies are employed, 
the most common being “bolus and continuous infusion”.  For boluses, four doses and seven 
durations were described.  There were ten different continuous infusion rates with over tenfold 
variation between the lowest and highest. (Table 4)   
142 (77.6%) use aminophylline, with 127 (89.4%) giving “bolus and infusion”.  132 (93%) give a bolus, 
of which 120 (91%) give 5mg/kg.  5 (3.8%) give each of 6mg/kg or 7.5mg/kg and one 10mg/kg.  120 
(91%) give the bolus over 20-30 minutes.  Nine continuous infusion rates were described, all at 
1mg/kg/hr or less, with 1mg/kg/hr being the most common (68.6%). 
173 (94.5%) use magnesium sulphate; all used a bolus with no subsequent infusion. 141 (81.5%) give 
40-50mg/kg over 20-30 minutes. 
 
 
  
Other therapies 
116 (62%) stated that more invasive therapy including intubation was outside their scope of 
practice.  Of 67 (36.7%) who intubate, 62 (93%) use ketamine for induction of anaesthesia.  41 (24%) 
use non-invasive ventilation, and 4 (2%) use Heliox.  Other therapies included adrenaline (4, 2.2%), 
high flow oxygen (4, 2.2%), calm environment (3, 1.6%), DNAse (2, 1.1%), physiotherapy (1, 0.5%), 
total histamine blockade (1, 0.5%), intravenous ketamine (1, 0.5%), or monteleukast (1, 0.5%).  
 
DISCUSSION 
In establishing baseline practice across a range of sites and clinicians in the UK and Ireland, we have 
demonstrated variation in management of acute severe childhood wheeze. This exists in assessment 
and treatment, especially inhaled and IV bronchodilator selection, dosage and frequency, reflecting 
the paucity of evidence underpinning recommendations.   
CPGs such as BTS/SIGN national guidance9 assist clinicians in healthcare decisions and are 
underpinned by best available evidence.  CPs translate and clarify CPGs, including timing and dosage 
of treatment, and as a result they streamline management plans across handovers, reduce variability 
and errors in care, prompt use of best evidence, improve education, and potentially shorten length 
of stay.14,16   The CPGs we collected were based on BTS/SIGN guidance9 varying mainly in 
bronchodilator selection/dosage and system processes.  40% had a wheeze CP, representing an 
opportunity to share best practice.  In future CPs should capitalise on available technology and be 
used across all healthcare settings, including primary care, EDs, and inpatient settings. 
Variations in inhaled therapy included delivery method, drug selection, dosage and frequency.  Most 
used MDIs in children with no oxygen requirement, though one-fifth always used nebulisers.  Most 
gave the BTS/SIGN salbutamol MDI dose, though some tended towards lower doses in younger 
children.  Ipratropium bromide use is more varied as in other healthcare systems, perhaps due to 
conflicting literature.13  However in a recent systematic review children treated with ipratropium 
  
bromide and salbutamol compared to salbutamol alone have lower rates of hospital admission, 
nausea and tremor, and greater improvement in lung function.17 
More than half used salbutamol as the first-line IV agent while fewer preferred magnesium sulphate 
or aminophylline, suggesting equipoise regarding which is most efficacious. To investigate this we 
asked participants whether they would enrol patients to a randomised controlled trial allocating 
salbutamol, aminophylline or magnesium sulphate as the first line IV agent, to which 148 (80.9%) 
responded positively.   
Uncertainty exists regarding the optimal dose and administration strategy, especially for salbutamol, 
contributed to by numerous dosage terminologies.  We defined these terms through reference to 
available CPGs, though some would reserve the term “loading” for a dose which is followed by 
continuous infusion and “bolus” for a dose not followed by an infusion.  There is threefold and 
tenfold variation in bolus doses and continuous infusion rates respectively, and infrequent usage of 
loading doses, reflecting the paucity of evidence on the pharmacokinetics of IV salbutamol.18  
BTS/SIGN guidelines suggest a bolus of 15micrograms/kg over 10 minutes, followed by an infusion of 
1-5micrograms/kg/minute if required with no loading dose described.  Key studies suggest a bolus of 
15micrograms/kg19 or a loading dose of 5micrograms/kg/minute for one hour.20,21  Respectively 
these are equivalent to 1.5micrograms/kg/minute19 (the lower end of guidance), or a total dose of 
300micrograms/kg20,21 (20 times that suggested by guidance).  In further analysing the dose given 
prior to any continuous infusion, there is 60-fold variation between a single 5micrograms/kg dose, 
and a dose of 5micrograms/kg/minute given for one hour. 
Knowledge translation may take several years,14 though, recent evidence may result in practice 
change.  For example, a recent trial of inhaled magnesium sulphate reported improvement in a 
subset of children,22,23 and oral dexamethasone may provide an alternative to prednisolone, 
appearing at least as effective and more palatable.24-29   
  
Variation may be reduced by dissemination of research and sharing of best practice across networks.  
There is therefore a need for rigorously conducted multicentre research on topics including 
development of a minimum data set, identification of wheeze phenotypes, and the optimal 
strategies for treatment of acute severe wheeze.  These include studies on inhaled bronchodilators 
in the first hour, IV bronchodilator selection, dexamethasone compared to prednisolone, and other 
therapies such as inhaled steroids.  Several of these were identified as important to clinicians 
through a research prioritisation exercise performed by PERUKI.30  Only in answering these questions 
can variation be reduced and clinical care improved in this important, common, and potentially life- 
threatening condition. 
 
LIMITATIONS 
This study relied on accurate reporting by individual clinicians.  However our approach allowed us to 
analyse practice of a large number of consultant clinicians from a number of regions, and our high 
response rate means we are confident we have identified key variations.  We did not focus on a 
wider range of practitioners, but this is reasonable given many EDs have a consultant-delivered 
service.  We have identified variation in practice, but cannot determine best practice.  However our 
methods allow assessment of variation, outline areas for implementation, and highlight areas in 
which there is a paucity of evidence.  We assessed a range of practice points in a short time and 
identified areas for investigation, the first of which has been completed31   
 
CONCLUSIONS 
Variation exists in the assessment and treatment of acute severe childhood wheeze across the UK 
and Ireland.  Key areas include inhaled and IV bronchodilator selection, dosage and frequency, 
reflecting the paucity of evidence.  We have identified opportunities for best practice dissemination 
and highlighted clinical questions which must be answered by robust multicentre research to 
improve clinical care of this common childhood condition. 
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WHAT IS KNOWN ON THIS TOPIC 
Childhood asthma is the most common chronic medical condition of childhood, and one of the most 
common reasons for attendance to urgent and emergency care and admission to hospital. 
National guidance exists for the management of acute childhood wheeze, though there is a paucity 
of evidence in some areas of practice. 
Variation in treatment and investigation of acute childhood wheeze has been demonstrated in other 
settings, and variation in hospitalisation rates across primary care trusts exists in our setting.  
 
WHAT THIS STUDY ADDS 
Across the UK & Ireland variation exists in the treatment of acute severe childhood wheeze, 
especially in inhaled and intravenous bronchodilator selection, dosage and frequency. 
We have identified key areas of variation, which require further exploration to determine their 
impact at the patient interface. 
There is an urgent need for multicentre studies to address the paucity of evidence for management 
of severe childhood wheeze to inform recommendations.  
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TABLES 
Table 1: Respondent characteristics 
 Number of 
respondents 
% of 
respondents 
Number of 
sites 
Country    
England 134 73.2 20 
Scotland 21 11.5 4 
Ireland 18  9.8 4 
Wales 7 3.8 1 
N Ireland 3 1.6 1 
Department    
Generic Emergency Department 73 39.9  
General Paediatrics/Child Health* 72 39.3  
Children’s Emergency Department 38 20.8  
Specialty    
General Paediatrics 63 34.4  
Paediatric Emergency Medicine 60 32.8  
Emergency Medicine (EM) 28 15.3  
EM with Paediatric subspecialty interest 18 9.8  
Consultant in Respiratory Paediatrics 7 3.8  
Other† 7 3.8  
*General paediatrics/child health includes those with other paediatric subspecialty interests 
†Other includes those with additional paediatric subspecialty interests 
 
  
Table 2:  Assessment of acute wheeze 
 Number % 
Do you assess and manage asthma and acute viral induced wheeze differently? 
No 113 61.7 
Yes 70 38.3 
Which of the following do you use to classify episode as severe?* 
Can’t complete sentences/too breathless to talk or feed 180 98.4 
Low oxygen saturations 177 96.7 
High respiratory rate 152 83.1 
High pulse rate 131 71.6 
Do you class the episode as severe if? 
More than one, not necessarily all are present 106 57.9 
Any are present in isolation 72 39.3 
Only if all are present 5 2.7 
Does your department have a Peak Expiratory Flow Rate meter? 
Yes 156 85.2 
No 16 8.7 
Don’t know 11 6.0 
If you have one, do you use it to determine severity? 
Sometimes 90 57.7 
No 44 28.2 
Yes 22 14.1 
*values given in survey as per British Thoracic Society guidance  
 
  
Table 3 – dosage regimes of inhaled salbutamol and ipratropium 
 <2 years 
n (%) 
2-<5 years 
n (%) 
5-<12 years 
n (%) 
≥12 years 
n (%) 
Same for all 
n (%) 
Salbutamol MDI (number of puffs) 
2 1 (0.6) 0 (0) 0 (0) 0 (0) 112 (60.2) 
4 2 (1.2) 2 (1.2) 0 (0) 0 (0)  
5 12 (7.4) 9 (5.4) 1 (0.6) 1 (0.6)  
6 20 (12.3) 16  (9.6) 6 (3.6) 2 (1.2)  
8 2 (1.2) 4 (2.4) 0 (0) 0 (0)  
10 112 (69.1) 125 (75.3) 148 (89.2) 146 (89.6)  
12 1 (0.6) 1 (0.6) 3 (1.8) 6 (3.7)  
Other 12 (7.4) 9 (5.4) 8 (4.8) 8 (4.9)  
Salbutamol nebuliser (dose in milligrams) 
1.25 3 (1.8) 0 (0) 0 (0) 0 (0) 16 (32.3) 
2.5 152 (90.5) 146 (84.4) 7 (4) 2 (1.2)  
5 7 (4.2) 20 (11.6) 155 (89.1) 166 (96)  
Other 6 (3.6) 7 (4) 12 (6.9) 5 (2.9)  
Ipratropium MDI (number of puffs) 
1 3 (5.7) 3 (5.8) 0 (0) 0 (0) 34 (19.5) 
2 24 (45.2) 22 (42.3) 17 (34) 16 (32)  
4 14 (26.4) 15 (28.8) 13 (26) 12 (24)  
5 2 (3.8) 2 (3.8) 1 (2) 1 (2)  
6 3 (5.7) 5 (9.6) 5 (10) 7 (14)  
8 0 (0) 0 (0) 7 (14) 8 (16)  
10 1 (1.9) 1 (1.9) 2 (4) 2 (4)  
Other 6 (11.3) 4 (7.7) 5 (10) 4 (8)  
Ipratropium nebuliser (dose in micrograms) 
62.5 12 (7.7) 1 (0.6) 0 (0) 0 (0) 27 (15.5) 
125 58 (37.2) 42 (26.9) 5 (3.2) 2 (1.3)  
250 73 (46.8) 104 (66.7) 97 (61.8) 65 (41.4)  
500 6 (3.8) 2 (1.2) 49 (31.2) 87 (55.4)  
Other 7 (4.5) 7 (4.5) 6 (3.8) 3 (1.9)  
Note: Figures in parentheses represent percentage based on number of people who give a dose in the age group  
MDI: Metered Dose Inhaler 
 
  
Table 4 – Intravenous salbutamol regimes 
 Number % 
Which regimen do you use for intravenous salbutamol 
Bolus then continuous infusion 126 68.3 
Loading dose then continuous infusion 12 6.6 
Continuous infusion 12 7.1 
Bolus only 5 2.7 
Bolus, then loading dose, then continuous infusion 7 3.8 
Don’t use 13 7.1 
Other 8 4.4 
Do you use a bolus dose? 
Yes 146 85.9 
No 24 14.1 
What dose do you give as a bolus? 
15 micrograms/kg 89 61 
5 micrograms /kg if <2 yr, 15 micrograms/kg if ≥2 yr  54 37 
5-10 micrograms/kg 1 0.7 
5 micrograms/kg 2 1.4 
Duration of bolus dose (minutes) 
10 68 46.6 
5 38 26 
15 15 10.3 
20 12 8.2 
5-10 9 6.2 
5-15 2 1.4 
30 2 1.4 
Do you give a loading dose 
No 149 87.6 
Yes 21 12.4 
What loading dose do you use? 
5 micrograms/kg/min 21 100 
What duration do you load over? (minutes) 
60 16 76.2 
60-120 5 23.8 
Do you use a continuous infusion? 
Yes 164 96.5 
No 6 3.5 
What dose regimen do you use (micrograms/kg/min) 
1-5 76 46.3 
1-2 52 31.7 
1 12 7.3 
0.5-6 9 5.5 
2-5 9 5.5 
1-3 2 1.2 
0.5-1 1 0.6 
0.6-1 1 0.6 
1-6 1 0.6 
5 1 0.6 
 
 
